By Fineline Cube 
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a Phase II study assessing the efficacy and safety of its HER2-targeted monoclonal antibody (mAb) HLX22 combined with trastuzumab deruxtecan. The study focuses on patients with HR-positive, HER2 low-expressing locally advanced or metastatic breast cancer who have experienced disease progression or intolerable toxic reactions following standard treatment.
HLX22: Development and Applications
HLX22, licensed from AbClon, Inc., is under development for the treatment of gastric cancer, breast cancer, and other solid tumors. This Phase II study marks a significant step in evaluating its potential in combination therapies for breast cancer, particularly in the HER2 low-expressing patient population.
Clinical Trial and Future Outlook
The initiation of this Phase II study highlights Henlius’s commitment to advancing innovative therapies for patients with limited treatment options. By combining HLX22 with trastuzumab deruxtecan, the trial aims to explore new treatment paradigms for advanced breast cancer, potentially improving outcomes for this challenging patient group.-Fineline Info & Tech